Drug Profile
Tisagenlecleucel - Novartis/University of Pennsylvania
Alternative Names: Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Novartis; Anti-CD19-chimeric-antigen-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-chimeric-immune-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-CIR-retroviral-vector-transduced-autologous-T-cell-therapy-Novartis; CART-019; CART-19; CART-19 cells; CART-19-cells-Novartis; CART19-Novartis; CD19-targeted-chimeric-antigen-receptor-immunotherapy-Novartis; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL-019; Kimria; Kymriah; LG-740; tisagenlecleucel; tisagenlecleucel-TLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Lentigen Corporation; University of Pennsylvania
- Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
- Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase III Non-Hodgkin's lymphoma
- Phase II Multiple myeloma
- No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Breast cancer; Lymphoma; Mantle-cell lymphoma; Mesothelioma; Ovarian cancer; Pancreatic cancer
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 10 Aug 2023 Novartis initiates a phase III trial for Follicular lymphoma (In adults, In the elderly, Second-line therapy or greater) (IV) in Australia (NCT05888493)
- 26 May 2023 Novartis completes a phase II BIANCA trial in Non-Hodgkin's lymphoma (In children, In adolescents, Second-line therapy or greater) in the US, Australia, Austria, Canada, Denmark, Finland, France, Italy, Japan, Netherlands, Norway, Spain, United Kingdom (IV) (NCT03610724)